Alnylam Pharmace. buy Vassago1
Start price
27.12.21
/
50%
€143.65
Target price
27.12.22
-
Performance (%)
-9.78%
End price
09.01.22
€129.60
Summary
This prediction ended on 09.01.22 with a price of €129.60. With a performance of -9.78%, the BUY prediction for Alnylam Pharmace. by Vassago1 closed slightly in the red. Vassago1 has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -1.377% | -1.377% | -27.266% |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% |
According to Vassago1 what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Cons
Risky Investment
Comments by Vassago1 for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.